General Electric Company (GE) is selling its biopharma business to Danaher for $21.4 billion, the company announced Feb. 25. With a definitive agreement signed between the two parties, GE’s previous plan to spin off its healthcare sector with its own initial public offering is likely put on hold, GE Chairman and CEO Larry Culp told CNBC.